Fatal Arrhythmic Risks in Cardiac Sarcoidosis With Mildly Impaired Cardiac Function

• DOI: 10.1016/j.jacasi.2023.07.006
• Publication Date: 2023-09-05T17:56:39Z
• Authors: Hiroyuki Kamada; Kohei Ishibashi; Yuichiro Miyazaki; Akinori Wakamiya; Nobuhiko Ueda; Kenzaburo Nakajima; Tsukasa Kamakura; Mitsuru Wada; Yoichi Takaya; Yuko Inoue; Koji Miyamoto; Satoshi Nagase; Takeshi Aiba; Yoshikazu Yazaki; Mitsuaki Isobe; Fumio Terasaki; Mitsuru Ohishi; Kengo F. Kusano
• Keywords: Concomitant

The prognosis and later fatal arrhythmia in cardiac sarcoidosis (CS) with relatively preserved function were unclear.This study aimed to evaluate the arrhythmic events patients CS mildly impaired function.Data collected from a nationwide Japanese cohort survey conducted 57 hospitals (n = 420); 322 left ventricular ejection fraction (LVEF) >35% investigated.Ventricular tachycardia (VT) manifestation was present 50 (16%) absent 272 (84%), of whom 36 (72%) 46 (17%), respectively, had an implantable cardioverter-defibrillator (ICD). Over median 5 years, 23 all-cause deaths 31 appropriate ICD discharges observed. In Kaplan-Meier analysis, death did not differ between without VT (P 0.660), although therapy significantly less used than those < 0.001). Of manifestation, 18 (VAEs), including 3 sudden 15 discharges. multivariate concomitant nonsustained (NSVT) atrioventricular block (AVB), lower LVEF, abnormal gallium-67 scintigraphy or 18F-fluorodeoxyglucose positron emission tomography heart (Ga/PET), NSVT Ga/PET at diagnosis independent predictors VAEs 0.008, P 0.021, 0.049, 0.024, respectively).If AVB, Ga/PET, is observed (LVEF >35%), should be considered as primary prevention.